BIAFW — bioAffinity Technologies, Inc.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1712762 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 1,351,527 422,891 -3,616,976 -3,630,610 7,945,252 3,098,366 4,283,866
Dec 2025 1,538,813 638,687 -3,190,963 -3,137,466 10,960,772 6,449,782 3,683,116
Sep 2025 1,446,066 503,855 -2,292,846 -5,051,084 11,546,369 7,669,195 2,644,171

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,914,307
Investing CF
$-15,445
Financing CF
$13,583,412
CapEx
$-69,877
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-72,184,674
Inventory
$77,887
Receivables
$685,235
ST Investments
—
EBIT TTM
$-15,800,991
Pretax Income TTM
$-15,844,600
Interest Exp TTM
$43,609
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,900,985
EBITDA
$-11,968,556
Free Cash Flow
$-6,909,285
Enterprise Value
—
Total Cash
$2,429,719
Total Debt
$1,435,005
Shares Out
—
Trailing EPS
—
Book Value
$8.34
ROE
-1860.2%
ROA
-125.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 6,107,959 -10,626,508 -14,909,754 10,960,772 3,683,116 7,277,656 -9,328,842
Dec 2024 9,362,022 -8,953,445 -9,039,831 6,513,667 3,911,631 2,602,036 -7,264,795
Dec 2023 2,532,499 -7,973,228 -7,937,011 8,221,552 3,366,297 4,855,255 -6,037,806
Dec 2022 4,803 -4,011,058 -8,154,113 12,182,125 1,138,682 11,043,443 -4,070,845

TTM Snapshot

Revenues TTM
$5,659,889
NetIncome TTM
$-15,879,947
OpCashFlow TTM
—
Assets (Latest)
$7,945,252
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
IQV IQVIA HOLDINGS INC. $42.61B $258.88 —
IDXX IDEXX LABORATORIES INC /DE $40.43B $513.14 —
INCY INCYTE CORP $22.85B $112.75 —
MEDP Medpace Holdings, Inc. $16.82B $602.70 —
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $14.35B $298.00 —

News headlines (Yahoo Finance, 1h cache)

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-09 16:30 · Yahoo
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-09 15:37 · Yahoo
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-08 17:30 · Yahoo
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-08 16:07 · Yahoo
bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test
2026-10-08 14:34 · Yahoo
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
2026-10-08 12:00 · Yahoo
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
2026-10-06 13:19 · Yahoo
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
2026-09-30 12:00 · Yahoo
bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection
2026-09-28 09:17 · Yahoo
bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference
2026-09-22 14:41 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.